Merck’s Vasotech (enalapril)
Executive Summary
Supplemental NDA for prevention of congestive heart failure in myocardial infarction patients is approvable Aug. 16. The indication was recommended for approval by the Cardiovascular and Renal Drugs Advisory Committee Feb. 19.